Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection

Veterinary Research

Volumn 45, Issue 1, 2014, Pages

  Kochinger, Stefanie ^a   Renevey, Nathalie ^a   Hofmann, Martin A ^a   Zimmer, Gert ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE; VP2 PROTEIN, BLUETONGUE VIRUS; VP5 PROTEIN, BLUETONGUE VIRUS;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BLUETONGUE; BLUETONGUE ORBIVIRUS; GENE VECTOR; GENETICS; IMMUNOLOGY; REPLICON; SERODIAGNOSIS; SHEEP; SHEEP DISEASE; VESICULAR STOMATITIS VIRUS; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; CAPSID PROTEINS; GENETIC VECTORS; NEUTRALIZATION TESTS; REPLICON; SHEEP; SHEEP DISEASES; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL VACCINES;

ANIMALIA; ARTHROPODA; BLUETONGUE VIRUS; BLUETONGUE VIRUS 8; MIRIDAE; OVIS ARIES; VESICULAR STOMATITIS VIRUS;

EID: 84902056252     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-45-64     Document Type: Article

References (46)

1. Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus-a new taxonomic group. Physiocochemical and serological studies. Borden EC, Shope RE, Murphy FA, J Gen Virol 1971 13 261 271 10.1099/0022-1317-13-2-261 4333714
2. Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus-a new taxonomic group. Electron microscopic studies. Murphy FA, Borden EC, Shope RE, Harrison A, J Gen Virol 1971 13 273 288 10.1099/0022-1317-13-2-273 4333715
3. Bluetongue virus: virology, pathogenesis and immunity. Schwartz-Cornil I, Mertens PP, Contreras V, Hemati B, Pascale F, Breard E, Mellor PS, MacLachlan NJ, Zientara S, Vet Res 2008 39 46 10.1051/vetres:2008023 18495078
4. Bluetongue disease in Swiss sheep breeds: clinical signs after experimental infection with bluetongue virus serotype 8. Worwa G, Thur B, Griot C, Hofmann M, MacLachlan JN, Chaignat V, Schweiz Arch Tierheilkd 2008 150 491 498 (in German) 10.1024/0036-7281.150.10.491 18821508
5. Vertical transmission of bluetongue virus serotype 8 virus in Dutch dairy herds in 2007. Santman-Berends IM, van Wuijckhuise L, Vellema P, van Rijn PA, Vet Microbiol 2010 141 31 35 10.1016/j.vetmic.2009.08.010 19713058
6. The impact of naturally-occurring, trans-placental bluetongue virus serotype-8 infection on reproductive performance in sheep. Saegerman C, Bolkaerts B, Baricalla C, Raes M, Wiggers L, de Leeuw I, Vandenbussche F, Zimmer JY, Haubruge E, Cassart D, De Clercq K, Kirschvink N, Vet J 2011 187 72 80 10.1016/j.tvjl.2009.11.012 20061168
7. Abortions, stillbirths and deformities in sheep at the Al-Ahsa oasis in eastern Saudi Arabia: isolation of a bluetongue serogroup virus from the affected lambs. Housawi FM, Abu Elzein EM, Ramadan RO, Gameel AA, Al-Afaleq AI, Al-Mousa J, Rev Sci Tech 2004 23 913 920 15861886
8. Epizootic congenital hydranencephaly and abortion in cattle due to bluetongue virus serotype 8 in the Netherlands. Wouda W, Peperkamp NH, Roumen MP, Muskens J, van Rijn A, Vellema P, Tijdschr Diergeneeskd 2009 134 422 427 19522347
9. Detection of a fourth orbivirus non-structural protein. Belhouchet M, Mohd Jaafar F, Firth AE, Grimes JM, Mertens PP, Attoui H, PLoS One 2011 6 25697 10.1371/journal.pone.0025697 22022432
10. Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Mertens PP, Brown F, Sangar DV, Virology 1984 135 207 217 10.1016/0042-6822(84)90131-4 6328750
11. Bluetongue virus replication, molecular and structural biology. Mertens PP, Diprose J, Maan S, Singh KP, Attoui H, Samuel AR, Vet Ital 2004 40 426 437 20422565
12. Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry. Hassan SS, Roy P, J Virol 1999 73 9832 9842 10559295
13. Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Zhang X, Boyce M, Bhattacharya B, Zhang X, Schein S, Roy P, Zhou ZH, Proc Natl Acad Sci U S A 2010 107 6292 6297 10.1073/pnas.0913403107 20332209
14. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Huismans H, van der Walt NT, Cloete M, Erasmus BJ, Virology 1987 157 172 179 10.1016/0042-6822(87)90326-6 3029956
15. Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. DeMaula CD, Bonneau KR, MacLachlan NJ, Virus Res 2000 67 59 66 10.1016/S0168-1702(00)00130-1 10773319
16. Structure of the bluetongue virus genome and its encoded proteins. Roy P, Marshall JJ, French TJ, Curr Top Microbiol Immunol 1990 162 43 87 2166648
17. Regional seroprevalence of bluetongue virus in cattle in Illinois and western Indiana. Boyer TC, Ward MP, Wallace RL, Singer RS, Am J Vet Res 2007 68 1212 1219 10.2460/ajvr.68.11.1212 17975976
18. Re-emergence of bluetongue, African horse sickness, and other orbivirus diseases. Maclachlan NJ, Guthrie AJ, Vet Res 2010 41 35 10.1051/vetres/2010007 20167199
19. Bluetongue in Europe: past, present and future. Wilson AJ, Mellor PS, Philos Trans R Soc Lond B Biol Sci 2009 364 2669 2681 10.1098/rstb.2009.0091 19687037
20. Impact of bluetongue virus infection on the international movement and trade of ruminants. MacLachlan NJ, Osburn BI, J Am Vet Med Assoc 2006 228 1346 1349 10.2460/javma.228.9.1346 16649936
21. In vivo and in vitro propagation and transmission of Toggenburg orbivirus. Planzer J, Kaufmann C, Worwa G, Gavier-Widen D, Hofmann MA, Chaignat V, Thur B, Res Vet Sci 2011 91 163 e168 10.1016/j.rvsc.2011.03.007 21458013
22. Recombinant vaccines against bluetongue virus. Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marin-Lopez A, Virus Res 2014 182 78 86 24287057
23. Understanding and altering cell tropism of vesicular stomatitis virus. Hastie E, Cataldi M, Marriott I, Grdzelishvili VZ, Virus Res 2013 176 16 32 10.1016/j.virusres.2013.06.003 23796410
24. Vesicular stomatitis virus: re-inventing the bullet. Lichty BD, Power AT, Stojdl DF, Bell JC, Trends Mol Med 2004 10 210 216 10.1016/j.molmed.2004.03.003 15121047
25. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Kalhoro NH, Veits J, Rautenschlein S, Zimmer G, Vaccine 2009 27 1174 1183 10.1016/j.vaccine.2008. 12.019 19135116
26. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus. Halbherr SJ, Brostoff T, Tippenhauer M, Locher S, Berger Rentsch M, Zimmer G, PLoS One 2013 8 66059 10.1371/journal.pone.0066059 23762463
27. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G, J Gen Virol 2005 86 1455 1465 10.1099/vir.0.80788-0 15831958
28. Rapid detection and quantitation of Bluetongue virus (BTV) using a Molecular Beacon fluorescent probe assay. Orru G, Ferrando ML, Meloni M, Liciardi M, Savini G, De Santis P, J Virol Methods 2006 137 34 42 10.1016/j.jviromet.2006.05.028 16876884
29. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. Berger Rentsch M, Zimmer G, PLoS One 2011 6 25858 10.1371/journal.pone.0025858 21998709
30. Virological and pathological findings in Bluetongue virus serotype 8 infected sheep. Worwa G, Hilbe M, Chaignat V, Hofmann MA, Griot C, Ehrensperger F, Doherr MG, Thur B, Vet Microbiol 2010 144 264 273 10.1016/j.vetmic.2010.01. 011 20153937
31. Detection of neutralizing antibodies against Bluetongue virus serotype 8 by an optimized plasma neutralization test. Worwa G, Chaignat V, Feldmann J, Thur B, J Virol Methods 2013 188 168 174 10.1016/j.jviromet.2012.08.027 23000751
32. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. Hoffmann M, Wu YJ, Gerber M, Berger-Rentsch M, Heimrich B, Schwemmle M, Zimmer G, J Gen Virol 2010 91 2782 2793 10.1099/vir.0.023978-0 20631091
33. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli S, Meyer G, Vaccine 2012 30 1609 1616 10.1016/j.vaccine.2011.12.108 22244980
34. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, Alpar O, Ortego J, Takamatsu HH, Mertens PP, Castillo-Olivares J, PLoS One 2013 8 60574 10.1371/journal.pone.0060574 23593251
35. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Lobato ZI, Coupar BE, Gray CP, Lunt R, Andrew ME, Vet Immunol Immunopathol 1997 59 293 309 10.1016/S0165-2427(97) 00084-6 9477479
36. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ, Vaccine 2007 25 672 678 10.1016/j.vaccine.2006.08.025 17059856
37. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N, PLoS One 2012 7 34425 10.1371/journal.pone.0034425 22511939
38. Evaluation of the humoral immune response in adult dairy cattle three years after vaccination with a bluetongue serotype 8 inactivated vaccine. Oura CA, Edwards L, Batten CA, Vaccine 2012 30 112 115 10.1016/j.vaccine.2011.10.100 22067262
39. Evaluation of the humoral immune responses in adult cattle and sheep, 4 and 2.5 years post-vaccination with a bluetongue serotype 8 inactivated vaccine. Batten CA, Edwards L, Oura CA, Vaccine 2013 31 3783 3785 10.1016/j.vaccine. 2013.06.033 23791548
40. Possible adverse reactions in sheep after vaccination with inactivated BTV vaccines. Gonzalez JM, Figueras L, Ortega ME, Lozano M, de Arcaute MR, Royo R, Cebrian LM, Ferrer LM, Farinas F, de Jalon JA, De las Heras M, Vet Rec 2010 166 757 758 10.1136/vr.b4849 20543167
41. Bluetongue vaccination in Europe. Zientara S, MacLachlan NJ, Calistri P, Sanchez-Vizcaino JM, Savini G, Expert Rev Vaccines 2010 9 989 991 10.1586/erv.10.97 20822340
42. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. Schwartz JA, Buonocore L, Suguitan A Jr, Hunter M, Marx PA, Subbarao K, Rose JK, J Virol 2011 85 4602 4605 10.1128/JVI.02491-10 21325423
43. Attenuated vesicular stomatitis viruses as vaccine vectors. Roberts A, Buonocore L, Price R, Forman J, Rose JK, J Virol 1999 73 3723 3732 10196265
44. Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge. Matsuo E, Celma CC, Boyce M, Viarouge C, Sailleau C, Dubois E, Breard E, Thiery R, Zientara S, Roy P, J Virol 2011 85 10213 10221 10.1128/JVI.05412-11 21795358
45. Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. Celma CC, Boyce M, van Rijn PA, Eschbaumer M, Wernike K, Hoffmann B, Beer M, Haegeman A, De Clercq K, Roy P, J Virol 2013 87 9856 9864 10.1128/JVI.01514-13 23824810
46. Vaccines against bluetongue in Europe. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S, Comp Immunol Microbiol Infect Dis 2008 31 101 120 10.1016/j.cimid.2007.07.006 17765305